GlaxoSmithKline collaborates with Chinese biotech for COVID-19 vaccine

GlaxoSmithKline, a UK-based pharma giant has teamed up Chinese company Xiamen Innovax Biotech to develop a vaccine against COVID-19. The vaccine candidate COVID-19 XWG-03 is being developed by Xiamen Innovax Biotech, along with researchers from Xiamen University. The role of GlaxoSmithKline in this collaboration will be to provide access to adjuvant for use in the vaccine. Adjuvants are added to certain vaccines to boost the immune response. GlaxoSmithKline had previously collaborated with Xiamen Innovax Biotech to develop the human papillomavirus vaccine in 2019. GlaxoSmithKline is also providing adjuvant technology to many other research organizations like China-based Clover Biopharmaceuticals. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit

Want to set up an online consultation for your practice, Click here